Bone marrow transplantation for acute lymphoblastic leukaemia

Area of Science:

• Hematology
• Oncology
• Stem Cell Transplantation

Background:

• Allogeneic bone marrow transplantation (BMT) has been a treatment for poor-risk acute lymphoblastic leukemia (ALL) for over two decades.
• Treatment outcomes and indications for BMT in ALL have evolved significantly.
• Chemotherapy advancements have influenced the perceived role of BMT, creating treatment controversies.

Purpose of the Study:

• To review the role and outcomes of allogeneic BMT in the treatment of poor-risk acute lymphoblastic leukemia (ALL).
• To define specific indications where BMT offers superior leukemia-free survival.
• To discuss challenges and future directions in BMT for ALL.

Main Methods:

• Review of long-term data and clinical experience with allogeneic BMT for acute lymphoblastic leukemia.
• Analysis of factors contributing to cure, including preparative regimens, graft-versus-leukemia effect, and post-transplant chemotherapy.
• Identification of specific high-risk ALL subgroups benefiting from BMT.

Main Results:

• Long-term leukemia-free survival rates exceed 60% for adults and 70% for children in first remission, and 30-40% in second remissions.
• BMT provides a better chance of survival in specific poor-risk categories: Philadelphia chromosome-positive ALL, remission induction failures, and relapsed pediatric ALL.
• Key factors for cure include myeloablative preparation, graft-versus-leukemia effect, and post-transplant chemotherapy.

Conclusions:

• Allogeneic BMT remains a crucial therapeutic option for selected poor-risk acute lymphoblastic leukemia patients.
• Addressing extramedullary leukemia, post-BMT relapse, and late effects are critical management areas.
• Future advancements, including unrelated donors and reduced transplant-related complications, will likely expand BMT use in poor-risk ALL.